CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Mizuho Medy Co Ltd Company Snapshot
Mizuho Medy Co Ltd operates within the Diagnostic substances sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mizuho Medy Co Ltd with three other pharmaceutical manufacturers in Asia: BioSino Bio-technology and Science Inc of China (2017 sales of 295.13 million Chinese Renmimbi [US$43.04 million] ), Kainos Laboratories, Inc. (4.70 billion Japanese Yen [US$41.53 million] of which 52% was immunological business), and Tellgen Corp which is based in China (302.89 million Chinese Renmimbi [US$44.17 million] of which 94% was Reagent Income).

Sales Analysis.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Mizuho Medy Co Ltd
  Stock Performance Chart for Mizuho Medy Co Ltd
 
  Stock Data: Recent Stock Performance:
  Current Price (12/7/2018): 2,337.00
(Figures in Japanese Yen)
1 Week -5.0%   13 Weeks -17.7%  
4 Weeks -7.7%   52 Weeks 21.2%  
 
Mizuho Medy Co Ltd Key Data:
  Ticker: 4595 Country: Japan
  Exchanges: TYO Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Diagnostic Substances
  2017 Sales 5,624,619,000
(Year Ending Jan 2018).
Employees: 157
  Currency: Japanese Yen Market Cap: 22,259,116,398
  Fiscal Yr Ends: December Shares Outstanding: 9,524,654
  Share Type: Common Closely Held Shares: 4,806,000
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.